New Redipor Broth Kit for operator aseptic broth transfer testing
Cherwell’s new Redipor Universal Operator Broth Transfer Kit.
Kit provides all the key elements required to carry out an operator aseptic broth transfer test.
Cherwell Laboratories, specialists in products for process validation and environmental monitoring, will be introducing a new Redipor Broth Kit at the Aseptic Preparation and Dispensing Medicines (APDM) Training Course, 8-12 July. At the Leeds Trinity University located course and exhibition, Cherwell will be exhibiting a selection of its prepared media, including its brand new Redipor Universal Operator Broth Transfer Kit, and microbial air samplers.
The new Redipor Universal Operator Broth Transfer Kit provides all the key elements required to carry out an operator aseptic broth transfer test, making it very relevant to delegates attending the APDM course. This test is a standard assessment for operators engaged in the aseptic processing of medicines prior to undertaking aseptic preparation activities, as well as for routine operator monitoring.
The kit comprises a 50 mL Tryptic Soy Broth (TSB) injection vial; three empty 30 mL sterile injection vials; a 100 mL TSB broth bag and one 10 mL TSB ampoule. The EVA infusion bag included is particularly appropriate to TPN compounding. All components are supplied by Cherwell Laboratories in a purpose-made corrugated plastic box, for ease of use.
Andrew Barrow, Sales Manager, Cherwell Laboratories, who will be attending the event commented: “For some years we have been supplying many different presentations of broth for media fill simulations, including our customers’ own bespoke containers. This year we have introduced the Redipor Operator Broth Transfer Kit as a standard kit which can be easily ordered from us ‘off the shelf’, as requested by the NHS.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.